Institute of Experimental Medicine


jacqueline-kelly-PeUJyoylfe4_0  helloquence-OQMZwNd3ThU_0  sarah-shaffer-O3gOgPB4sRU_0

Mikhail Galagudza, MD, DSc
Director of the Institute
Professor and Corresponding Member of the Russian Academy of Sciences

Institute of Experimental Medicine

The Institute of Experimental Medicine is a structural unit of Almazov National Medical Research Centre. Since 2017, it has had two units: the Centre for Experimental Biomodeling and the Preclinical Translational Research Centre.

The Institute of Experimental Medicine is a unique facility combining a nursery for the common types of laboratory animals (rodents, fish and tailless amphibians, pigs) and fully equipped laboratories for all types of research, including preclinical studies to evaluate the safety and efficacy of drugs.

Main activity

The Institute conducts experimental studies in compliance with GLP regulations to investigate the mechanisms underlying the onset and development of cardiovascular, blood and endocrine diseases as well as to develop and implement the new medical technologies that improve the quality of prevention, diagnosis and treatment of these diseases.

The Institute conducts preclinical studies to test the safety and efficacy of new drugs using SPF animals, introduces the results of research into clinical practice and training process as part of the translational medicine concept.

Possibilities for preclinical studies

  • Assessment of the toxicological profile of drugs (animal condition monitoring, biochemistry, pathology)
  • Aseptic surgery in chronic experiments
  • Full description of the cardiovascular system functions

Major tasks

  • Study of the pharmacokinetics, safety and specific activity of intravenous nicotinamide riboside administration in doxorubicin cardiomyopathy
  • Development of technologies for magnetic drug delivery to the targeted area
  • Role of metalloproteinases in the tumor pathogenesis and activation of the hemostasis system during tumor growth
  • Development of solid-phase granules for contact hemomodulation and activation of reparative processes in various injuries (burns, wounds, diabetes mellitus)
  • Development of theranostic agents based on biodegradable polymeric and protein nanocarriers
  • Development of a software system for remote myocardial conditioning based on local abdominal decompression
  • Development and optimization of toxicity testing protocol for substances with a molecular weight of more than 3 kDa in fish (Zebra fish)
  • Development and preclinical testing of surgical fluorescence imaging techniques

Structure of the Institute

Centre for Experimental Biomodeling

Preclinical Translational Research Centre

  • Preclinical Research Group
  • Veterinary Service
    — Department of Biological Test Systems and Biomodels
    — Rodent Vivarium
    — Sterilization Department
  • Neurobiology Research Group
  • Archives
  • Engineering Department
  • Pharmaceutical Department

Training and education

The Institute of Experimental Medicine has been actively involved in the educational process. Since 2015, training has been offered as part of the translational medicine concept in the following areas:

  • Principles of a modern vivarium and research using SPF animals
  • General principles of surgery in SPF rodents and surgical modeling of cardiovascular disease
  • General principles of working with laboratory animals: manipulations, surgery, necropsy
  • High-Quality Biomedical Experiment
Major publications

Ehrenfeld M., Tincani A., Andreoli L., Cattalini M., Greenbaum A., Kanduc D., Alijotas-Reig J., Zinserling V., Semenova N., Amital H., Shoenfeld Y. Covid-19 and autoimmunity. Autoimmunity Reviews. 2020;19 (8):102597. IF 7,80.

Mariniello M., Petruzzelli R., Wanderlingh L.G., La Montagna R., Carissimo A., Pane F., Amoresano A., Ilyechova E. Y., Galagudza M. M., Catalano F., Crispino R., Puchkova L. V., Medina D. L., Polishchuk R. S. Synthetic lethality screening identifies FDA-approved drugs that overcome ATP7B-mediated tolerance of tumor cells to cisplatin. Cancers (Basel). 2020; 12 (3):608. IF 6,13.

Pochkaeva E., Podolsky N., Zakusilo D., Petrov A., Charykov N., Vlasov T., Penkova A., Vasina L., Murin I., Sharoyko V., Semenov K. Fullerene derivatives with amino acids, peptides and proteins: From synthesis to biomedical application. PROGRESS IN SOLID STATE CHEMISTRY. 2020; DOI: 1016/j.progsolidstchem.2019.100255. IF 6,35.

Smirnova E. Y., Chizhov A. V., Zaitsev A. V. Presynaptic GABAB receptors underlie the antiepileptic effect of low-frequency electrical stimulation in the 4-aminopyridine model of epilepsy in brain slices of young rats. Brain Stimulation. 2020;13 (5):1387—1395. IF 6,60.

Mariniello M., Petruzzelli R., Wanderlingh L.G., La Montagna R., Carissimo A., Pane F., Amoresano A., Ilyechova E. Y., Galagudza M. M., Catalano F., Crispino R., Puchkova L. V., Medina D. L., Polishchuk R. S. Synthetic lethality screening identifies FDA-approved drugs that overcome ATP7B-mediated tolerance of tumor cells to cisplatin. Cancers (Basel). 2020;12 (3): ID 608 (эл.рес.). doi: 10.1007/s00441-019-03130-7.

Borshchev, Y.Y., Uspensky, Y.P., Galagudza, M.M. Pathogenetic pathways of cognitive dysfunction and dementia in metabolic syndrome. Life Sciences. 2019; 237: ID 116932 (эл.рес.). DOI: 10.1016/j.lfs.2019.116932.

Borshchev, Y.Y., Minasian, S.M., Burovenko, I.Y., Borshchev, V.Y., Protsak, E.S., Semenova, N.Y., Borshcheva, O.V., Galagudza, M.M. Effects of tetracycline on myocardial infarct size in obese rats with chemically-induced colitis. PLoS ONE. 2019; 14 (11), ID e0225185 (эл. ресурс). DOI: 10.1371/journal.pone.0225185.

Fedorova, OV; Fadeev, AV; Grigorova, YN; Marshall, CA; Zernetkina, V; Kolodkin, NI; Agalakova, NI; Konradi, AO; Lakatta, EG; Bagrov, AY. Cardiotonic Steroids Induce Vascular Fibrosis Via Pressure-Independent Mechanism in NaCl-Loaded Diabetic Rats. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 2019; 74 (5): 436-442. DOI: 10.1097/FJC.0000000000000730.

Baysa, A; Fedorov, A; Kondratov, K; Ruusalepp, A; Minasian, S; Galagudza, M; Popov, M; Kurapeev, D; Yakovlev, A; Valen, G; Kostareva, A; Vaage, J; Stenslokken, KO. Release of Mitochondrial and Nuclear DNA During On-Pump Heart Surgery: Kinetics and Relation to Extracellular Vesicles. JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH. 2019; 12 (3): 184-192. DOI: 10.1007/s12265-018-9848-3.

Knyazeva, A; Krutikov, A; Golovkin, A; Mishanin, A; Pavlov, G; Smolina, N; Hushkina, A; Sejersen, T; Sjoberg, G; Galagudza, M; Kostareva, A. Time- and Ventricular-Specific Expression Profiles of Genes Encoding Z-Disk Proteins in Pressure Overload Model of Left Ventricular Hypertrophy. FRONTIERS IN GENETICS. 2019; 9: ID 684 (эл.ресурс). DOI: 10.3389/fgene.2018.00684.

Belostotskaya, G.B., Nerubatskaya, I.V., Galagudza, M.M. Two mechanisms of cardiac stem cell-mediated cardiomyogenesis in the adult mammalian heart include formation of colonies and cell-in-cell structures. 2018; 9 (75):  34159-34175. DOI: 10.3389/fncel.2017.00264.

Karpov, AA; Udalova, DV; Pliss, MG; Galagudza, MM. Can the outcomes of mesenchymal stem cell-based therapy for myocardial infarction be improved? Providing weapons and armour to cells. CELL PROLIFERATION. 2017; 50 (2): e12316 (эл.рес). DOI: 10.1111/cpr.12316.

Toropova, YG; Golovkin, AS; Malashicheva, AB; Korolev, DV; Gorshkov, AN; Gareev, KG; Afonin, MV; Galagudza, MM. In vitro toxicity of FemOn, FemOn-SiO2 composite, and SiO2-FemOn core-shell magnetic nanoparticles. INTERNATIONAL JOURNAL OF NANOMEDICINE. 2017; 12: 593-603. DOI:10.2147/IJN.S122580.

Sonin, D; Papayan, G; Pochkaeva, E; Chefu, S; Minasian, S; Kurapeev, D; Vaage, J; Petrishchev, N; Galagudza, M. Features of the terahertz spectra of iron oxide nanoparticles in a silicon dioxide shell and of iron oxide and hydroxide nanoparticles. JOURNAL OF OPTICAL TECHNOLOGY. 2017; 84 (8): 515-520. DOI: 10.1364/JOT.84.000515.

Papayan, GV; Galagudza, MM; Minasyan, SM; Kishalov, AA; Zhurba, VM. Rat ceruloplasmin: a new labile copper binding site and zinc/copper mosaic. METALLOMICS. 2017; 9 (12): 1828—1838. DOI: 10.1039/c7mt00157f.

Knyazev A.N., Avrova N.F., Vlasova Yu.A., Alekseeva O.S., Krivchenko A.I., Demchenko I.T., Belekhova M.G., Kenigfest N.B., Belostotskaya G.B., Golovanova T.A., Nerubatskaya I.V., Galagudza M.M., Shpakov A.O., Derkach K.V., Giiemar D.M., Tsitseroshin M.N., Shepovalnikov A.N., Galperina E.I., Panasevich E.A., Kats E.E. et al. Evolutionary Physiology and Biochemistry — Advances and Perspectives. Croatia: Nationai and Library in Zagreb, 2018. – 234 p. ISBN 978-953-51-51-3857-0


Patent No. 2716596, issued on 13.03.2020, Application No. 2019128217 dated 06.09.2019
«A method for reducing the size of myocardial ischemia-reperfusion injury using quinacrine»
Authors: Sonin D.L., Pochkaeva E.I., Papayan G.V., Petrishchev N.N., Zaitseva E.A., Novruzova K.K., Volobuev E.Yu., Galagudza M.M.

Patent No. 2675353, issued on 18.12.2018, Application No. 2018119575 dated 28.05.2018
«A method for modeling chronic thromboembolic pulmonary hypertension»
Authors: Karpov A.A., Lomakina A.M., Cherepanov D.E., Anikin N.A., Krasnova M.V., Ivkin D.Yu., Galagudza M.M.

Software Registration Certificate No. 2018665061, issued on 29.11.2018, Application No. 2018661604 dated 22.10.2018
«Software for digital processing of histology images of the necrosis area (black shadow)»
Authors: Borshchev V.Yu., Burovenko I.Yu., Borshchev Yu.Yu., Galagudza MM, Korolev DV

Patent No. 2622983, issued on 21.06.2017, Application No. 2016130494 dated 25.07.2016
«Method for intraoperative imaging of myocardial ischemia-reperfusion injury»
Authors: Papayan G.V., Petrishchev N.N., Galagudza M.M., Sonin D.L., Minasyan S.M.

Patent No. 2619854, issued on 18.05.2017, Application No. 2015142268 dated 05.10.2015
Testing unit for magnetic delivery of nanoparticles into the vascular system (options)”
Authors: Korolev D.V., Afonin M.V., Galagudza M.M., Shutkevich V.V


Centre for Experimental Biomodeling
Address: 15B Parkhomenko street, St. Petersburg
Тел.: +7 (812) 702-51-68
Preclinical Translational Research Centre
Address: 43 Dolgoozernaya street, St. Petersburg


Уведомляем вас, что в соответствии с Федеральным законом от 06.03.2006 № 35-ФЗ «О противодействии терроризму» в Центре Алмазова введен комплекс дополнительных мер по безопасности, направленный на предотвращение террористических актов. В целях обеспечения безопасности граждан и целостности объектов инфраструктуры при посещении Центра Алмазова проводится дополнительный личный осмотр, осмотр вещей и автотранспорта. Отказ от соблюдения мер по безопасности может послужить причиной недопуска на территорию Центра Алмазова. Просим с пониманием отнестись к введенным мерам по безопасности.

С уважением, Администрация Центра Алмазова